Psychiatry · Eating DisordersTrial Updateclinicalmid-term

Pilot Study of Mobile App for Binge Eating in Adolescents

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 12:32:03 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The pilot study of a mobile app for binge eating in adolescents represents a significant advancement in digital therapeutics within the psychiatric and eating disorder fields. Its outcomes could reshape treatment paradigms and influence competitive positioning in adolescent mental health interventions. Regulatory context from MHRA (Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis) supports the near-term read. Assessment grounded in 20 ranked evidence items (6 high-relevance).

Strategic Assessment

The strongest clinical anchor is Project VIBE: Virtual Intervention for Binge Eating in Adolescents (ClinicalTrials.gov), entity match (national institute of diabetes and digestive and kidney diseases). In Psychiatry · Eating Disorders, 2 regulatory and 4 competitive items passed relevance filtering for National Institute of Diabetes and Digestive and Kidney Diseases. Successful outcomes from this pilot could lead to increased market share for digital therapeutic solutions, impacting revenue streams for companies involved in adolescent mental health treatments.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. As this is a pilot study, immediate regulatory implications are minimal; however, future developments may require compliance considerations for digital health interventions.

Key Opportunities

Successful outcomes from this pilot could lead to increased market share for digital therapeutic solutions, impacting revenue streams for companies involved in adolescent mental health treatments.
FDA Commissioner's National Priority Voucher Program. The Commissioner's National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.
Upside for National Institute of Diabetes and Digestive and Kidney Diseases may improve if Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) (ClinicalTrials.gov) delivers favorable follow-through.
The implications of digital therapeutics in their strategies, especially in the context of adolescent mental health.

What Would Change This Assessment

This becomes more urgent if Monitor feedback from participants regarding app usability and effectiveness, as well as any subsequent studies or partnerships that may arise.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Commissioner's National Priority Voucher (CNPV) Pilot Program
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Project VIBE: Virtual Intervention for Binge Eating in Adolescents
ClinicalTrials.govhigh relevance
Entity match (national institute of diabetes and digestive and kidney diseases)
FDA document
View source
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
ClinicalTrials.govhigh relevance
Entity match (national institute of diabetes and digestive and kidney diseases)
FDA document
View source
Feasibility Study of the FARAFLEX Mapping and PFA System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ultra-processed Food Consumption and Health Pilot Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA
Humanexa Signalsmedium relevance
Moderate corpus alignment

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

National Institute of Diabetes and Digestive and Kidney Diseases
adolescent mental health sector
digital therapeutics market

Commercial impact

medium

Successful outcomes from this pilot could lead to increased market share for digital therapeutic solutions, impacting revenue streams for companies involved in adolescent mental health treatments.

Regulatory impact

low

As this is a pilot study, immediate regulatory implications are minimal; however, future developments may require compliance considerations for digital health interventions.

What to watch

Monitor feedback from participants regarding app usability and effectiveness, as well as any subsequent studies or partnerships that may arise.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.